Revenue
2010
2011
2012
2013
2014
2015
2015
2018
2019
2020
2021
2022
2023
2024
2025
Abvc Biopharma, Inc. (ABVC)
Price$1.15Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2021
2022
2023
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2015
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 · Dec 31 | 2017 · Sep 30 | 2016 | 2015 · Dec 31 | 2015 · Sep 30 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296,000 | $0 | $152,430 | $969,783 | $355,797 | $483,045 | $701,719 | $6,956 | — | — | — | $50.0M | $3,360 | $0 | $7,787 | $5,714 | $3,190 | $14,860 |
| Gross profit | $0 | $508,826 | −$149,607 | $683,368 | $350,711 | $464,329 | $681,582 | −$178,324 | — | — | −$32 | — | $2,839 | $0 | — | — | — | — |
| Gross margin | 0.00% | — | −98.15% | 70.47% | 98.57% | 96.13% | 97.13% | −2,563.60% | — | — | — | — | 84.49% | — | — | — | — | — |
| Research & development | $121,085 | $179,272 | $1.1M | $2.7M | $1.0M | $549,658 | $1.0M | $988,721 | $3.2M | $3.2M | $10.0M | — | — | — | — | — | — | — |
| Operating expenses | $7.2M | $5.2M | $6.6M | $15.8M | $12.1M | $9.0M | $4.1M | $2.6M | $4.1M | — | $11.0M | — | $35,120 | $70 | $185,046 | $1.1M | $1.9M | — |
| Operating income | −$7.2M | −$4.7M | −$6.8M | −$15.1M | −$11.7M | −$8.5M | −$3.5M | −$2.8M | −$4.1M | −$4.0M | −$11.0M | — | — | — | −$177,259 | −$1.1M | −$1.9M | −$1.9M |
| Operating margin | −2,415.97% | — | −4,439.24% | −1,558.54% | −3,290.07% | −1,760.87% | −492.90% | −40,031.10% | — | — | — | — | — | — | −2,276.35% | −20,004.31% | −59,180.66% | −12,715.16% |
| EBITDA | −$7.1M | −$4.7M | −$6.7M | −$15.1M | −$11.7M | −$8.5M | −$3.4M | −$2.7M | — | — | — | — | — | — | −$153,400 | −$1.1M | −$1.9M | −$1.8M |
| EBITDA margin | −2,407.41% | — | −4,420.52% | −1,556.08% | −3,286.70% | −1,753.18% | −485.05% | −39,404.15% | — | — | — | — | — | — | −1,969.95% | −19,425.92% | −58,109.22% | −12,410.67% |
| Net income | −$7.9M | −$4.9M | −$7.8M | −$16.4M | −$12.8M | −$10.6M | −$3.9M | −$6.1M | −$4.2M | −$4.1M | −$11.0M | — | −$32,281 | −$23,235 | −$226,352 | −$1.1M | −$1.2M | −$1.9M |
| Net profit margin | −2,671.81% | — | −5,109.26% | −1,693.50% | −3,608.47% | −2,193.08% | −560.51% | −87,184.16% | — | — | — | — | −960.74% | — | −2,906.79% | −18,718.57% | −38,202.23% | −12,793.14% |
| Basic EPSper basic share | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$5.10 | -$5.00 | -$2.10 | -$3.60 | -$3.60 | -$3.60 | -$10.80 | — | -$1.80 | -$1.80 | $0.00 | -$7.20 | -$55.80 | -$423,000.00 |
| Diluted EPSper diluted share | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$5.10 | -$5.00 | -$2.10 | -$3.60 | -$3.60 | -$3.60 | -$10.80 | — | -$1.80 | -$1.80 | $0.00 | -$7.20 | -$55.80 | -$423,000.00 |
Owners
Reported shareholders
1.45%of listed shares
VANGUARD CAPITAL MANAGEMENT LLC374.5K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | 1.45%374.5K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.88%228.04K shares |
VANGUARD FIDUCIARY TRUST CO | 0.38%97.36K shares |
STATE STREET CORP | 0.28%72.8K shares |
CITADEL ADVISORS LLC | 0.28%72.09K shares |
BlackRock, Inc. | 0.22%56.44K shares |
NORTHERN TRUST CORP | 0.19%48.64K shares |
XTX Topco Ltd | 0.19%48.28K shares |
PANAGORA ASSET MANAGEMENT INC | 0.14%36.68K shares |
UBS Group AG | 0.13%34.12K shares |
JANE STREET GROUP, LLC | 0.08%20.06K shares |
CITIGROUP INC | <0.01%540 shares |
LifeSteps Financial, Inc. | <0.01%300 shares |
ROYAL BANK OF CANADA | <0.01%17 shares |
Caitong International Asset Management Co., Ltd | <0.01%6 shares |
Percentages use 25.77M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data